The Medicare GLP-1 Bridge may hold the key to Eli Lilly's market share.
CMS launches Medicare GLP-1 Bridge to offer select beneficiaries fixed-cost access to GLP-1 drugs from July 2026 through 2027.
For investors in Lilly, that may help answer a much bigger question: Will the obesity-drug business end up being even greater than Wall Street now expects? That's the $12.8 billion question for Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results